eResearch Issues Perspective on Microbix Biosystems Inc.

About this update from Microbix Biosystems Inc.

[{"type":"text","content":"\neResearch Issues Perspective on Microbix Biosystems Inc.\n\n Jun. 24, 2011 (Baystreet.ca) -- MicrobixBiosystems Inc. (TSX-V: MBX) is a biotechnology company leveragingits long-standing core virology business to develop products targeted to largeglobal market opportunities.TheCompany’s potentially more-lucrativelarge-market pipeline of products include: Kinlytic (Urokinase), VIRUSMAX™(Virus Yield Enhancement Technology), and LumiSort™ (livestock sex selectiontechnology). In addition, the Companyhas established a JV in Hunan, China for the manufacture and distribution ofinfluenza vaccines using VIRUSMAX™ technology.Microbixhas received a notice from the U.S. Patent and Trademark Office, allowing allclaims of its first pending U.S. patent application for LumiSort™ sperm-sexingtechnology for the livestock industries. The Company will exercise its optionto request the issuance of the LumiSort™ patent once it takes additionalstrategic steps to strengthen its position.To readthe complete Perspective, click here: http://www.eresearch.ca/_report/MBX_062311-B.pdf eResearch is preparing acomprehensive research report on Microbix Biosystems Inc. This report willcontain a Recommendation, a 12-month Target Price, and analyst views andopinions. About Us: eResearch is a primary source for professional investment research,focused primarily on small- and mid-cap companies. Our research and analysis isof institutional quality, and has the potential for reaching millions of globalinvestors through our extensive electronic distribution network.eResearch posts all its reports andarticles on its website, www.eresearch.ca,and subscription is FREE.Contact:eResearch: Bob Weir, CFA, Managing Director,Research ServicesTelephone:(416) 703-6258 Ext 221; E-mail: [email protected] \n\n\n\n","length":2175,"tagName":"div"}]

More updates from Microbix Biosystems Inc.